Abstract 734P
Background
In RUBY (NCT03981796), dostarlimab (D)+carboplatin-paclitaxel (CP) demonstrated significant OS benefits vs placebo (PBO)+CP in pts with pA/rEC. Differential response rates alone insufficiently describe the impact on long-term outcomes, in part because of high response rates with CP, albeit with a lack of durability. Response-based modeling may describe OS benefits associated with D+CP. This analysis investigated the impact of response on OS in the intent-to-treat population of RUBY.
Methods
In this post hoc exploratory OS analysis, surviving pts with evaluable disease were grouped by investigator-assessed objective response at 3 months (3-mo landmark). Landmarking eliminates immortal time bias. Pts with complete/partial response were classified as responders; those with stable or progressed disease were classified as nonresponders. Postlandmark OS was assessed using Kaplan-Meier methods and Cox proportional hazards models. Landmark analyses based on response at 1.5 or 4.5 mo were explored in sensitivity analyses.
Results
Overall, 196 pts in D+CP and 200 in PBO+CP were evaluable; 122 and 107, respectively, were responders; 74 and 93, respectively, were nonresponders at the 3-mo landmark. For responders, median (mo [95% CI]) postlandmark OS was not reached (NR) for D+CP (NR [NR-NR]) or PBO+CP (NR [18.5-NR]). For nonresponders, median OS was NR (21.6-NR) for D+CP and 26.8 (15.2-NR) for PBO+CP. HRs and postlandmark OS probabilities are shown in the table. Sensitivity analyses yielded similar results.
Conclusions
Outcomes associated with response to dostarlimab+CP were favorable compared with response to PBO+CP, reflecting the improved durability of benefit. OS rates suggest potential long-term benefits in responders and nonresponders. These findings provide further support for the use of D+CP as a standard of care in pts with pA/rEC. Table: 734P
Postlandmark OS rates among responders and nonresponders
Responders | Nonresponders | |||
D+CP | PBO+CP | D+CP | PBO+CP | |
3-mo landmark, n | 122 | 107 | 74 | 93 |
12-mo OS, % | 88 | 82 | 71 | 68 |
18-mo OS, % | 78 | 64 | 66 | 57 |
Median (95% CI), mo | NR (NR-NR) | NR (18.5-NR) | NR (21.6-NR) | 26.8 (15.2-NR) |
HR (95% CI) | 0.50 (0.31-0.81) | 0.76 (0.46-1.25) | ||
Sensitivity analyses | ||||
1.5-mo landmark, n | 121 | 112 | 78 | 95 |
12-mo OS, % | 87 | 80 | 73 | 71 |
18-mo OS, % | 80 | 63 | 67 | 57 |
Median (95% CI), mo | NR (NR-NR) | 22.6 (19.9-NR) | NR (23.1-NR) | 28.3 (16.7-NR) |
HR (95% CI) | 0.48 (0.30-0.77) | 0.76 (0.46-1.23) | ||
4.5-mo landmark, n | 116 | 104 | 70 | 82 |
12-mo OS, % | 87 | 75 | 73 | 70 |
18-mo OS, % | 78 | 61 | 69 | 59 |
Median (95% CI), mo | NR (NR-NR) | NR (17.5-NR) | NR (21.3-NR) | 25.3 (15.3-NR) |
HR (95% CI) | 0.52 (0.32-0.85) | 0.79 (0.46-1.35) |
Clinical trial identification
NCT03981796.
Editorial acknowledgement
Medical editorial assistance was provided by Nucleus Global, an Inizio company, and funded by GSK.
Legal entity responsible for the study
GSK.
Funding
This study was funded by GSK.
Disclosure
M.R. Mirza: Financial Interests, Personal, Advisory Role: AstraZeneca, Biocad, GSK, Karyopharm, Merck, Roche, Zailab; Financial Interests, Personal, Speaker’s Bureau, Honoraria: AstraZeneca, GSK; Financial Interests, Personal, Stocks or ownership: Karyopharm; Financial Interests, Institutional, Research Funding: Apexigen, AstraZeneca, GSK, Ultimovacs; Financial Interests, Institutional, Research Funding, Trial Chair: Deciphera ; Financial Interests, Personal, Member of Board of Directors: Karyopharm. C. Mathews: Financial Interests, Institutional, Research Funding: AvengeBio Astellas Pharma, AstraZeneca, Deciphera, EMD Serono, Genentech, Genmab, GSK, Merck, Moderna, The National Cancer Institute, Regeneron, Seagen, Syros. A. Koliadi: Financial Interests, Personal, Speaker, Consultant, Advisor: Eisai, GSK. L. Gilbert: Financial Interests, Institutional, Research Grant: Alkermes, AstraZeneca, Clovis, Corcept Therapeutics, Esperas, GOG Foundation, GSK, ImmunoGen, IMV, Karyopharm, K-Group Beta, Merck Sharp &Dohme, Mersana Therapeutics, Novocure GmbH, OncoQuest Pharmaceuticals, Roche, Shattuck Labs, Sutro BioPharma, Tesaro; Financial Interests, Personal, Speaker, Consultant, Advisor: GSK, Merck; Financial Interests, Personal, Speaker’s Bureau, Honoraria: CanariaBio, Eisai, Eisai-Merck, GOG Foundation, GSK, ImmunoGen, Kora Healthcare, Merck; Financial Interests, Personal, Financially compensated role, Support for attending meetings and/or travel: EndomEra, GOG Foundation, GSK, Merck, Zentalis; Financial Interests, Personal, Advisory Board: CanariaBio, Eisai, Eisai-Merck, GOG Foundation, GSK, ImmunoGen, Kora Healthcare, Merck. B.M. Slomovitz: Financial Interests, Personal, Speaker, Consultant, Advisor: Aadi Biosciences, AstraZeneca, BioNTech, Clovis Oncology, Eisai, Genmab, Genentech, Gilead, GSK, Incyte, Karyopharm, Merck, Novartis, Novocure, Regeneron, Seagen; Financial Interests, Personal, Speaker’s Bureau, Honoraria: Seagen. B.J. Monk: Financial Interests, Personal, Speaker, Consultant, Advisor: Agenus, Akeso Biopharma, Amgen, Aravive, Bayer, Elevar, EMD Merck, Genmab/Seagen, GOG Foundation, Gradalis, ImmunoGen, Iovance, Karyopharm, MacroGenics, Mersana, Myriad, Novartis, Novocure, Pfizer, Puma, Regeneron, Sorrento, US Oncology Research, VBL; Financial Interests, Personal, Speaker’s Bureau, Honoraria: AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: Clovis, Eisai, Merck, Roche/Genentech, Tesaro/GSK. P. Braly: Financial Interests, Institutional, Research Funding: GSK. D. Black: Financial Interests, Institutional, Research Grant: GSK; Financial Interests, Personal, Membership or affiliation, Membership fees: GOG Partners Investigational Council ; Financial Interests, Personal, Other, Medical Director/ Owner: Trials365, LLC. S.J. Lubinga: Financial Interests, Personal, Full or part-time Employment: GSK; Financial Interests, Personal, Stocks/Shares: GSK. D.J. Sharpe: Financial Interests, Institutional, Full or part-time Employment: Parexel International; Financial Interests, Institutional, Other, Organization received funds to conduct statistical research: Bristol Myers Squibb, GSK. M.A. Powell: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Clovis Oncology, Eisai, GSK, Merck, Seagen, Tesaro. All other authors have declared no conflicts of interest.
Resources from the same session
682TiP - A phase I, first-in-human study of DS-1471 in patients with advanced/metastatic solid tumors
Presenter: Shigehiro Koganemaru
Session: Poster session 01
683TiP - A phase I study of PARP inhibitor (niraparib) plus HSP90 inhibitor (pimitespib) in solid tumors: The NiraPim (EPOC2102) study
Presenter: Hiromichi Nakajima
Session: Poster session 01
684TiP - A phase I, open-label, multicenter, dose escalation and expansion study of HM97662 (EZH1/2 dual inhibitor) as a single agent in patients with advanced or metastatic solid tumors
Presenter: Bhumsuk Keam
Session: Poster session 01
685TiP - A phase I, multicenter trial (“KinLET”) of [177Lu]Lu-edotreotide for treatment of somatostatin receptor positive solid tumors or lymphoma, in patients two to less than 18 years of age
Presenter: Maria Cristina Mata Fernandez
Session: Poster session 01
687TiP - A phase I, first in human study of TORL-4-500 in patients with advanced cancer
Presenter: Jonathan Goldman
Session: Poster session 01
688TiP - Phase I dose escalation trial to evaluate safety and preliminary efficacy of ACR246, an innovative 5T4- antibody drug conjugate (ADC), in patients (pts) with advanced solid tumors
Presenter: Xihui Hu
Session: Poster session 01
689TiP - A phase I/IIa trial of Aurora-A inhibitor (JAB-2485) in adult patients with advanced solid tumors
Presenter: Vaia Florou
Session: Poster session 01
690TiP - HERTHENA-PanTumor01: A global phase II trial of HER3-DXd in metastatic solid tumors
Presenter: Thomas Powles
Session: Poster session 01
691TiP - PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation
Presenter: Alison Schram
Session: Poster session 01